Stryker Corporation
HealthcareNYSE:SYK · New York Stock Exchange
+$8.18 today
Vol 1.65M · Avg 2.49M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
14.5%
avg 16.1%
ROIC
8.8%
avg 10.6%
ROA
6.8%
avg 7.3%
Analysis
ROE is currently the strongest return metric at 14.5% versus its period average of 16.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Kevin A. Lobo | Chairman & CEO | $4.72M | — | 61 | $248,723.00 | 0.06% |
Spencer S. Stiles | President & COO | $1.74M | — | 49 | $76,027.00 | 0.02% |
J. Andrew Pierce | Group President of MedSurg & Neurotechnology | $1.73M | — | 52 | $18,465.00 | <0.01% |
Preston Wells | Vice President & Chief Financial Officer | $1.49M | — | 49 | $6,498.00 | <0.01% |
Viju S. Menon | Group President of Global Quality & Operations | $1.42M | — | 58 | $22,100.00 | <0.01% |
Robert S. Fletcher | Vice President & Chief Legal Officer | $895,895.00 | — | 55 | $10,707.00 | <0.01% |
Dragana Bunjevac | President of Eastern Europe, Middle East & Africa | — | — | — | — | — |
Jason Beach | VP and Group CFO of MedSurg & Neurotechnology | — | — | — | — | — |
Debra S. King | VP and Chief Digital & Information Officer | — | — | 54 | $7,569.00 | <0.01% |
Nick Mead | Vice President of Investor Relations | — | — | — | — | — |
William E. Berry Jr. | Vice President & Chief Accounting Officer | — | — | 60 | $3,426.00 | <0.01% |
Robert C. Cohen | Chief Technology Officer and Vice President of Global R&D - Joint Replacement | — | — | — | $10,707.00 | <0.01% |
Dana S. McMahon | Vice President & Chief Compliance Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
59
$544.12M
Net Sentiment
$544.12M
Net selling
Most Active
STRYKER RONDA E
46 transactions
1–10 of 59
Analysis
Insiders reported 0 buys worth $0.00 and 59 sells worth $544.12M over the last 12 months. That adds up to net selling of $544.12M. STRYKER RONDA E was the most active insider with 46 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +3.7% | +12.9% (15yr)5 analysts |
| Revenue | N/A | N/A | +4.7% | +9.3% (15yr)11 analysts |
| Net Income | N/A | N/A | +3.5% | +12.9% (15yr)11 analysts |
| EBIT | N/A | N/A | +5.5% | +7.6% (15yr)11 analysts |
Analysis
Recent growth has been strongest in EBIT at +5.5% over three years. Forward estimates point to Net Income at +12.9% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Amgen Inc.
NASDAQ:AMGN
$190.83B
Gilead Sciences, Inc.
NASDAQ:GILD
$155.38B
Pfizer Inc.
NYSE:PFE
$149.18B
Danaher Corporation
NYSE:DHR
$127.33B
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
$112.63B
Sanofi
NASDAQ:SNY
$106.45B
Medtronic plc
NYSE:MDT
$103.11B
McKesson Corporation
NYSE:MCK
$94.81B
HCA Healthcare, Inc.
NYSE:HCA
$85.73B
Boston Scientific Corporation
NYSE:BSX
$69.81B
Who manages SYK?
Stryker Corporation (SYK) lists 13 active executives. The top listed executive is Kevin A. Lobo, Chairman & CEO.
Are SYK insiders buying or selling?
Recent insider activity shows net selling of $659.38M.
Explore More
Continue the stock analysis
Jump to another research area for this company.